Eric Vivier

Eric Vivier elucidated the role of NKG2A as a major inhibitory checkpoint on NK cells and cytotoxic T cells, leading to the development of monalizumab, the first anti-NKG2A antibody to enter clinical trials for cancer immunotherapy. His comprehensive mapping of NK cell receptor repertoires revealed how combinatorial expression patterns determine functional potential against tumors. He co-founded Innate Pharma and has driven the translation of NK cell biology into clinical checkpoint immunotherapy approaches targeting innate immune receptors.